Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.56 |
| ▸ | USP2 | O75604 | 9/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.56 |
| ▸ | LMNA | P02545 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 8/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | TP53 | P04637 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281016 | 0.88 | CYP1A2 (0.67) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20280943 | 0.88 | CYP1A2 (0.61) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20280951 | 0.88 | CYP1A2 (0.66) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20280933 | 0.87 | GBA1 (0.75) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20280961 | 0.85 | CYP1A2 (0.59) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20280947 | 0.84 | CYP1A2 (0.56) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20280952 | 0.83 | CYP1A2 (0.54) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20280922 | 0.82 | CYP1A2 (0.58) | GBA1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20281071 | 0.81 | HTR1A (0.62) | CYP1A2CYP3A4CYP2D6CYP2C19USP2 | |
| SCHEMBL20267012 | 0.81 | HTT (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-11718609-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-08-08 | — | — | US | disclosed |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | Beta Therapeutics Pty Ltd (AU) | 2021-05-06 | — | — | US | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| WO-2018107200-A1 | HEPARANASE INHIBITORS AND USE THEREOF | Beta Therapeutics Pty Ltd (AU) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | GBA1 153/4885CYP1A2 4837/4885CYP3A4 4824/4885 |
| US-20210130338-A1 | Heparanase Inhibitors and Use Thereof | HPSE, HEXD, ENGASE | GBA1 15/4885CYP1A2 1462/4885CYP3A4 1237/4885 |
| US-11718609-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | GBA1 15/4885CYP1A2 1462/4885CYP3A4 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.